Skip to main content
Journal cover image

Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.

Publication ,  Journal Article
Tcheng, JE
Published in: Am Heart J
September 1995

Novel antithrombotic and antiplatelet agents may help reduce the short-term risk of ischemic complications and the long-term risk of restenosis in patients undergoing coronary revascularization procedures. Recent clinical trials suggest that, compared with heparin, direct thrombin inhibitors (such as hirudin and hirulog) offer a predictable dose-response effect on the activated partial thromboplastin time without a concomitant increase in bleeding. Among the newer antiplatelet agents, the platelet integrin glycoprotein IIb/IIIa inhibitors (including c7E3 Fab and Integrelin) have generated the greatest interest. Clinical trial data have shown that c7E3 Fab (administered in conjunction with heparin) significantly reduces ischemic events and improves clinical outcomes. In phase II trials, Integrelin has also shown similar effects. The primary limitations have been an increase in heparin-associated bleeding, which suggests that the safety profile may be enhanced by careful adjustment of the heparin dose implementation of other patient management guidelines. The safety and efficacy data obtained in future trials should shed more light on the appropriate roles of these drugs in interventional cardiology.

Duke Scholars

Published In

Am Heart J

DOI

ISSN

0002-8703

Publication Date

September 1995

Volume

130

Issue

3 Pt 2

Start / End Page

673 / 679

Location

United States

Related Subject Headings

  • Safety
  • Platelet Aggregation Inhibitors
  • Peptides
  • Immunoglobulin Fab Fragments
  • Humans
  • Fibrinolytic Agents
  • Eptifibatide
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tcheng, J. E. (1995). Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J, 130(3 Pt 2), 673–679. https://doi.org/10.1016/0002-8703(95)90305-4
Tcheng, J. E. “Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.Am Heart J 130, no. 3 Pt 2 (September 1995): 673–79. https://doi.org/10.1016/0002-8703(95)90305-4.
Tcheng, J. E. “Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.Am Heart J, vol. 130, no. 3 Pt 2, Sept. 1995, pp. 673–79. Pubmed, doi:10.1016/0002-8703(95)90305-4.
Journal cover image

Published In

Am Heart J

DOI

ISSN

0002-8703

Publication Date

September 1995

Volume

130

Issue

3 Pt 2

Start / End Page

673 / 679

Location

United States

Related Subject Headings

  • Safety
  • Platelet Aggregation Inhibitors
  • Peptides
  • Immunoglobulin Fab Fragments
  • Humans
  • Fibrinolytic Agents
  • Eptifibatide
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Antibodies, Monoclonal